Achieving lipid goals in real life: The DISCOVERY-UK study

British Journal of Cardiology

Volumn 13, Issue 1, 2006, Pages 72-76

  Middleton, Alan ^a   Fuat, Ahmet ^b  

^a Fowey River Practice   (United Kingdom)

^b Carmel Medical Practice   (United Kingdom)

Author keywords

Hypercholesterolaemia; Low density lipoprotein cholesterol; Randomised controlled trial; Statin

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTHRALGIA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; MYALGIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STATISTICAL ANALYSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 33644615602     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
2. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361:1149-58.
3. Brady AJB, Norrie J, Ford I. Failure to achieve cholesterol targets with statins in UK general practice - the Performance For Life study PCCS Annual Meeting and AGM, 3-4 October 2003. (www.pccs.org.uk/Abstract Form.htm Accessed 16.07.04).
4. Evans PH, Luthra M, Pike C et al. NSF lipid targets in patients with CHD: Are they achievable in a real-life primary care setting? Br J Cardiol 2004;11:71-4.
5. Foley KA, Simpson RJ Jr, Crouse JR 3rd et al. Effectiveness of statin titration on low density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79-81.
6. Olsson AG, McTaggart F, Raza A. Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303-28.
7. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;92:152-60.
8. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003;91:11-17C; discussion 17-19C.
9. Second Joint Task Force of European and other Societies. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-503.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
11. De Backer G, Abrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prev Rehabil 2003;10(suppl 1):S2-S78.
12. Department of Health. National Service Framework for Coronary Heart Disease. London: Department of Health, 2000.
13. Boyle R. DoH explains thinking behind National Service Framework for Coronary Heart Disease. BMJ 2000;321:1083.
14. Brady AJB, Betteridge DJ. Prevalence and risks of undertreatment with statins. Br J Cardiol 2003;10:218-19.
15. Minhas R. Statins in primary care: Bridging the treatment gap. Br J Cardiol 2004;11:487-91.
16. The British Medical Association. Investing in general practice: The new General Medical Services contract. London: The British Medical Association, February 2003 (www.bma.org.uk/ap.nsf/Content/investinggp Accessed 23.11.04).
17. Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am J Cardiol 2004;94: 882-8.
18. Palmer SJ, Brady AJ, Ratcliffe AE. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. Int J Clin Pract 2003;57:792-800.
19. Smith DG, Leslie SJ, Szucs TD et al. Cost of treating to a modified European Atherosclerosis Society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. Clin Drug Invest 1999;17:185-93.
20. Ward S, Lloyd Jones M et al. Technology assessment report commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence. Statins for the prevention of coronary events. London: National Institute of Clinical Excellence, January 2005 (www.nice.org.uk/pdf/Statins_assessment_report.pdf Accessed 8.11.05).
21. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
22. La Rosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
23. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary. BMJ 2004;328:634-40.
24. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.